Visas 1 - 5 av 5 resultat för sökning 'Ana Oaknin (14956029)', Sökningstid: 0,01s Förfina resultatet
  1. 1
    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... av Stephanie Lheureux (16797697)

    Publicerad 2025
    Övriga upphovsmän:
    Lägg till i favoriter
    Sparad:
  2. 2
    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... av Stephanie Lheureux (16797697)

    Publicerad 2025
    Övriga upphovsmän:
    Lägg till i favoriter
    Sparad:
  3. 3
    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... av Stephanie Lheureux (16797697)

    Publicerad 2025
    Övriga upphovsmän:
    Lägg till i favoriter
    Sparad:
  4. 4
    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... av Stephanie Lheureux (16797697)

    Publicerad 2025
    Övriga upphovsmän:
    Lägg till i favoriter
    Sparad:
  5. 5
    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

    Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP... av Stephanie Lheureux (16797697)

    Publicerad 2025
    Övriga upphovsmän:
    Lägg till i favoriter
    Sparad:

Sökverktyg: